A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period Adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK-6096 in Patients with Primary Insomnia
Summary
The purpose of the research study is to evaluate the safety, effectiveness and tolerability of an investigational medication in subjects with primary insomnia.
How Can You Qualify?
Persons aged 18-64 with primary insomnia for at least 3 months may qualify. All study related visits, laboratory work, study medication, transportation and study related procedures are provided at no cost. Qualified participants may also receive compensation for time and travel.
Principal Investigator
AC Patel, MD
Contact
Mark Schrier, Katie Yrosh, Lisa Bess
-
(570)207-3945
Location
Sleep Lab of Northeastern Pennsylvania - Clarks Summit, Pennsylvania
